BiotechTube

naloxegol + non-PAMORA laxative

Pre-clinicalTerminated
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Induced Constipation

Conditions

Opioid Induced Constipation

Trial Timeline

Sep 1, 2016 → Nov 1, 2021

NCT ID
NCT02813369

About naloxegol + non-PAMORA laxative

naloxegol + non-PAMORA laxative is a pre-clinical stage product being developed by Kyowa Kirin for Opioid Induced Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02813369. Target conditions include Opioid Induced Constipation.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02813369Pre-clinicalTerminated

Competing Products

20 competing products in Opioid Induced Constipation

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + NaloxegolAstraZenecaPhase 1
33
NKTR-118 + Usual careAstraZenecaPhase 3
77
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
85

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85